Madison-Shira Hossack

Madison-Shira Hossack

Auto-generated profile, based on publicly available information

Madison-Shira Hossack

Princess Margaret Cancer Centre 2 Research Institute , Toronto, Canada

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2026 in Cancer Research Communications
Verified
Journal Article
Open access
AWAlison J. Wu
Alison J. Wu
NLNeil Lin
Neil Lin
JSJie Su
Jie Su
CLCherie Lin
Cherie Lin
MHMadison-Shira Hossack
Madison-Shira Hossack
JKJennifer Y.Y. Kwan
Jennifer Y.Y. Kwan
Lymphedema is a chronic complication of breast cancer treatment, and early intervention is crucial to reduce morbidity. This study evaluated the role of blood-based cytokine biomarkers in the prognostication of breast cancer–related lymphedema (BCRL) to improve risk prediction. A secondary analysis of inflammatory biomarkers for BCRL was performed using a previously published cohort of 147 patients with breast cancer who had undergone serum cytokine profiling during their treatment at the Princess Margaret Cancer Centre from 2010 to 2014. Prognostic cytokine variables for lymphedema were selected by regression analysis and independence from known clinical risk factors. Regression-based modeling was employed to integrate prognostic variables for the prediction of lymphedema occurrence. We identified the immunostimulatory cytokine IFNα2A as a potential biomarker for lymphedema development [OR, 3.10; 95% confidence interval (CI), 1.05–9.51; P = 0.042], independent from known clinical risk factors. Furthermore, Kaplan–Meier analysis demonstrated 3-year lymphedema-free survival of 95% (90%–100%) versus 85% (77%–94%) for below versus above median concentrations of IFNα2A (P = 0.026). In combination with an established clinical risk regression-based model, patients identified as high risk based on clinical factors alone were able to be correctly reclassified as low risk by IFNα2A in 31% (eight of 26) of cases. Our combined logistic regression model using both IFNα2A and clinical risk score achieved an AUC of 0.895 (95% CI, 0.796–0.971) and Brier score of 0.101 (95% CI, 0.061–0.149), representing a favorable improvement compared with the logistic regression model using clinical risk factors alone. IFNα2A in combination with established clinical risk factors may be useful for improving BCRL prognostication. Significance: The cytokine IFNα2A was identified as a potentially complementary biomarker to improve the stratification of high- and low-risk patients for BCRL. This will help enable earlier intervention to reduce long-term morbidity for those at high risk for lymphedema while minimizing burdensome interventions for those at low risk.

3 March 2026
Verified
Other
Open access
AWAlison J. Wu
Alison J. Wu
NLNeil Lin
Neil Lin
JSJie Su
Jie Su
CLCherie Lin
Cherie Lin
MHMadison-Shira Hossack
Madison-Shira Hossack
JKJennifer Y.Y. Kwan
Jennifer Y.Y. Kwan
Clinical characteristics of the study population.

3 March 2026
Verified
Other
Open access
AWAlison J. Wu
Alison J. Wu
NLNeil Lin
Neil Lin
JSJie Su
Jie Su
CLCherie Lin
Cherie Lin
MHMadison-Shira Hossack
Madison-Shira Hossack
JKJennifer Y.Y. Kwan
Jennifer Y.Y. Kwan
Net reclassification improvement by IFNα2a.

3 March 2026
Verified
Other
Open access
AWAlison J. Wu
Alison J. Wu
NLNeil Lin
Neil Lin
JSJie Su
Jie Su
CLCherie Lin
Cherie Lin
MHMadison-Shira Hossack
Madison-Shira Hossack
JKJennifer Y.Y. Kwan
Jennifer Y.Y. Kwan
Table S1. Summary of baseline serum cytokine levels measured at pre-radiotherapy.

3 March 2026
Verified
Other
Open access
AWAlison J. Wu
Alison J. Wu
NLNeil Lin
Neil Lin
JSJie Su
Jie Su
CLCherie Lin
Cherie Lin
MHMadison-Shira Hossack
Madison-Shira Hossack
JKJennifer Y.Y. Kwan
Jennifer Y.Y. Kwan
IFNα2 levels in patients with breast cancer. Preradiotherapy IFNα2 was measured in 62 patients with breast cancer. Patients were grouped by their lymphedema (LE) status at 18 months after cancer treatment. Data are plotted as median with IQR. Two-tailed P value is 0.157 (Mann–Whitney test).

3 March 2026
Verified
Other
Open access
AWAlison J. Wu
Alison J. Wu
NLNeil Lin
Neil Lin
JSJie Su
Jie Su
CLCherie Lin
Cherie Lin
MHMadison-Shira Hossack
Madison-Shira Hossack
JKJennifer Y.Y. Kwan
Jennifer Y.Y. Kwan
Lymphedema is a chronic complication of breast cancer treatment, and early intervention is crucial to reduce morbidity. This study evaluated the role of blood-based cytokine biomarkers in the prognostication of breast cancer–related lymphedema (BCRL) to improve risk prediction. A secondary analysis of inflammatory biomarkers for BCRL was performed using a previously published cohort of 147 patients with breast cancer who had undergone serum cytokine profiling during their treatment at the Princess Margaret Cancer Centre from 2010 to 2014. Prognostic cytokine variables for lymphedema were selected by regression analysis and independence from known clinical risk factors. Regression-based modeling was employed to integrate prognostic variables for the prediction of lymphedema occurrence. We identified the immunostimulatory cytokine IFNα2A as a potential biomarker for lymphedema development [OR, 3.10; 95% confidence interval (CI), 1.05–9.51; P = 0.042], independent from known clinical risk factors. Furthermore, Kaplan–Meier analysis demonstrated 3-year lymphedema-free survival of 95% (90%–100%) versus 85% (77%–94%) for below versus above median concentrations of IFNα2A (P = 0.026). In combination with an established clinical risk regression-based model, patients identified as high risk based on clinical factors alone were able to be correctly reclassified as low risk by IFNα2A in 31% (eight of 26) of cases. Our combined logistic regression model using both IFNα2A and clinical risk score achieved an AUC of 0.895 (95% CI, 0.796–0.971) and Brier score of 0.101 (95% CI, 0.061–0.149), representing a favorable improvement compared with the logistic regression model using clinical risk factors alone. IFNα2A in combination with established clinical risk factors may be useful for improving BCRL prognostication.Significance:The cytokine IFNα2A was identified as a potentially complementary biomarker to improve the stratification of high- and low-risk patients for BCRL. This will help enable earlier intervention to reduce long-term morbidity for those at high risk for lymphedema while minimizing burdensome interventions for those at low risk.